{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:10:05Z","timestamp":1783782605398,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed\/refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed\/refractory HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%. During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4 extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL patients.<\/jats:p>","DOI":"10.1038\/s41408-019-0265-x","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T15:04:53Z","timestamp":1576076693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi"],"prefix":"10.1038","volume":"9","author":[{"given":"A.","family":"Broccoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Botto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"P.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Fondazione Italiana Linfomi ONLUS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"265_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch, D. C. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trials. Lancet 341, 1051\u20131054 (1993).","journal-title":"Lancet"},{"key":"265_CR2","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz, N. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomized trial. Lancet 359, 2065\u20132071 (2002).","journal-title":"Lancet"},{"key":"265_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai, S. et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk. Lymphoma 54, 2531\u20132533 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"265_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda, A. et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann. Oncol. 16, 625\u2013633 (2005).","journal-title":"Ann. Oncol."},{"key":"265_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.15639","volume":"184","author":"A Broccoli","year":"2019","unstructured":"Broccoli, A. & Zinzani, P. L. The role of transplantation in Hodgkin lymhoma. Br. J. Haematol. 184, 93\u2013104 (2019).","journal-title":"Br. J. Haematol."},{"key":"265_CR6","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz, A. J. et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Blood 116, 4934\u20134937 (2010).","journal-title":"Blood"},{"key":"265_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","volume":"148","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz, C. H. et al. High-dose chemoradiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br. J. Haematol. 148, 890\u2013897 (2010).","journal-title":"Br. J. Haematol."},{"key":"265_CR8","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier, R. et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin\u2019s lymphoma responding to prior salvage therapy. Haematologica 97, 1073\u20131079 (2012).","journal-title":"Haematologica"},{"key":"265_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bjh.12824","volume":"165","author":"RD Gentzler","year":"2014","unstructured":"Gentzler, R. D. et al. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Br. J. Haematol. 165, 793\u2013800 (2014).","journal-title":"Br. J. Haematol."},{"key":"265_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz, A. J. et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 16, 284\u2013292 (2015).","journal-title":"Lancet Oncol."},{"key":"265_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J. Clin. Oncol. 30, 2183\u20132189 (2012).","journal-title":"J. Clin. Oncol."},{"key":"265_CR12","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen, R., Gopal, A. K. & Smith, S. E. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128, 1562\u20131566 (2016).","journal-title":"Blood"},{"key":"265_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz, A. J. et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol. 31, 456\u2013460 (2013).","journal-title":"J. Clin. Oncol."},{"key":"265_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.clml.2015.02.023","volume":"15","author":"PL Zinzani","year":"2015","unstructured":"Zinzani, P. L. et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin\u2019s lymphoma: experience with 27 patients. Clin. Lymphoma Myeloma Leuk. 15, 404\u2013408 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"265_CR15","doi-asserted-by":"crossref","unstructured":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132, 40\u201348 (2018).","DOI":"10.1182\/blood-2017-11-815183"},{"key":"265_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133067 (2014).","journal-title":"J. Clin. Oncol."},{"key":"265_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan, M., Gallamini, A. & Haioun, C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk. Lymphoma 50, 1257\u20131260 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"265_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce, A. S. et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132, 40\u201348 (2018).","journal-title":"Blood"},{"key":"265_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."},{"key":"265_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","volume":"19","author":"OA O\u2019Connor","year":"2018","unstructured":"O\u2019Connor, O. A. et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicenter, single-arm, phase 1-2 trial. Lancet Oncol. 19, 257\u2013266 (2018).","journal-title":"Lancet Oncol."},{"key":"265_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","volume":"3","author":"M Picardi","year":"2019","unstructured":"Picardi, M. et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 3, 1546\u20131552 (2019).","journal-title":"Blood Adv."},{"issue":"22","key":"265_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood.V128.22.1834.1834","volume":"128","author":"Ryan D Cassaday","year":"2016","unstructured":"Cassaday, R. D. et al. Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I\/II study. Blood 128, 1834 (2016).","journal-title":"Blood"},{"key":"265_CR23","unstructured":"Hagenbeek, A. et al. Transplant BRaVE: combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: a phase 1 dose-escalation study. Haematologica 101, e151\u2013e153 (2016)."},{"issue":"4","key":"265_CR24","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz, R. et al Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of atrial by the Spanish GELTAMO Group). Ann. Oncol. 30, 612\u2013620 (2019).","journal-title":"Annals of Oncology"},{"key":"265_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera, A. F. et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131, 1183\u20131194 (2018).","journal-title":"Blood"},{"key":"265_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bjh.15639","volume":"184","author":"A Broccoli","year":"2019","unstructured":"Broccoli, A. & Zinzani, P. L. The role of transplantation in Hodgkin lymphoma. Br. J. Haematol. 184, 93\u2013104 (2019).","journal-title":"Br. J. Haematol."},{"key":"265_CR27","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2016.66.4466","volume":"34","author":"A Santoro","year":"2016","unstructured":"Santoro, A. et al. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J. Clin. Oncol. 34, 3293\u20133299 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0265-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0265-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:15:47Z","timestamp":1671207347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0265-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0265-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,11]]},"assertion":[{"value":"24 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"100"}}